沙美特罗替卡松在中重度慢阻肺急性期患者治疗中的临床疗效研究  

Clinical efficacy of salmeterol fluticasone in patients with moderate to severe chronic obstructive pulmonary disease at acute stage

作　　者：宋刚 SONG Gang(Huludao Second People's Hospital,Huludao 125000,China)

机构地区：[1]辽宁省葫芦岛市第二人民医院,125000

出　　处：《中国实用医药》2023年第4期115-117,共3页China Practical Medicine

摘　　要：目的探究沙美特罗替卡松在中重度慢性阻塞性肺疾病(慢阻肺)急性期患者治疗中的临床疗效,为临床实践提供理论依据。方法100例中重度慢阻肺急性期患者,随机分为参照组和研究组,每组50例。参照组患者给予常规治疗,研究组患者在参照组基础上加用沙美特罗替卡松治疗。比较两组患者治疗前后肺功能指标(呼气峰流速、第1秒用力呼气容积),治疗前后生活质量评分,不良反应发生情况。结果治疗前,两组患者的呼气峰流速、第1秒用力呼气容积比较差异无统计学意义(P>0.05);治疗后,研究组患者的呼气峰流速(7.79±1.45)L/s、第1秒用力呼气容积(1.93±0.27)L均明显高于参照组的(6.12±1.62)L/s、(1.47±0.18)L,差异具有统计学意义(P<0.05)。研究组患者治疗前生活质量评分为(72.78±4.68)分,治疗后为(92.45±6.38)分;参照组患者治疗前生活质量评分为(72.69±4.74)分,治疗后为(85.97±5.27)分。两组治疗前的生活质量评分比较,差异无统计学意义(P>0.05);治疗后,研究组患者的生活质量评分明显高于参照组,差异具有统计学意义(P<0.05)。研究组患者的不良反应发生率6.00%明显低于参照组的20.00%,差异具有统计学意义(P<0.05)。结论中重度慢阻肺急性期患者实施沙美特罗替卡松治疗,能有效改善肺功能,提升生活质量,减少不良反应,治疗效果显著,可在临床推广及使用。Objective To investigate the clinical efficacy of salmeterol fluticasone in patients with moderate to severe chronic obstructive pulmonary disease at acute stage,so as to provide theoretical basis for clinical practice.Methods A total of 100 patients with moderate to severe chronic obstructive pulmonary disease at acute stage were randomly divided into a reference group and a research group,with 50 patients in each group.Patients in the reference group received conventional treatment,and patients in the research group received ssalmeterol fluticasone on the basis of the reference group.Both groups were compared in terms of lung function indexes(peak expiratory flow rate,forced expiratory volume in one second),quality of life score before and after treatment,and the occurrence of adverse reactions.Results Before treatment,there was no statistically significant difference in peak expiratory flow rate and forced expiratory volume in one second between the two groups(P>0.05).After treatment,the peak expiratory flow rate(7.79±1.45)L/s and the forced expiratory volume in one second(1.93±0.27)L in the research group were significantly higher than(6.12±1.62)L/s and(1.47±0.18)L in the reference group,and the differences were statistically significant(P<0.05).The quality of life score in the research group was(72.78±4.68)points before treatment and(92.45±6.38)points after treatment;the quality of life score in the reference group was(72.69±4.74)points before treatment,and(85.97±5.27)points after treatment.Before treatment,there was no statistically significant difference in quality of life scores between the two groups(P>0.05).After treatment,the quality of life score in the research group were significantly higher than that in the reference group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the research group was 6.00%,which was significantly lower than 20.00%in the reference group,and the difference was statistically significant(P<0.05).Conclusion Salmeterol fluti

关 键 词：沙美特罗替卡松 中重度慢性阻塞性肺疾病 急性期 生活质量 

分 类 号：R563.9[医药卫生—呼吸系统]